COVID-19 Human IgG PharmaGenie ELISA Kit (S1 RBD) (SBRS1722)

The S1 RBD target represents the receptor-binding domain of the SARS-CoV-2 spike protein, a region critical for viral entry via ACE2 interaction. Assay Genie's indirect ELISA platform detects human IgG antibodies raised against this immunodominant epitope, supporting seroprevalence surveillance, vaccine response monitoring, and prior infection studies in clinical or research settings.

The kit accommodates flexible sample types including dried blood spots, plasma, saliva, and serum, enabling non-invasive collection strategies for large-scale epidemiological screening. Researchers commonly pair this S1 RBD-specific assay with nucleocapsid-based ELISA kits to differentiate between vaccination-induced and natural-infection antibody profiles.

Reagents should be stored refrigerated at 4 degrees C and protected from light, with the standard 96-assay microplate format supporting moderate-throughput laboratory workflows. Intended for research use only, this kit provides a quantitative readout suitable for tracking humoral immunity over time following infection or immunization.